CRIANN boosts bandwidth in French research and education network with Adtran FSP 3000
5.11.2024 11:00:00 EET | Business Wire | Press release
Adtran today announced that the Centre Régional Informatique et d’Applications Numériques de Normandie (CRIANN) is using its FSP 3000 optical transport technology and ALM fiber monitoring platform to boost the capacity and resilience of its research and education network, thanks to the financial support of the Normandy Region. By integrating Adtran’s solution, the Normandy-based supercomputing center and provider of high-performance digital infrastructure is ensuring faster and more reliable connectivity for the region’s scientific and academic institutions. Adtran’s Elite partner Axians also played a key role in the installation and continues to deliver maintenance and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104047734/en/
Adtran’s technology is helping CRIANN drive high-speed, secure and ultra-reliable connectivity throughout its research and education network. (Photo: Business Wire)
“Our fiber network promotes innovation and the advancement of scientific knowledge. We support academic institutions in several ways, including by enabling data-intensive simulations and AI research for which high-speed, secure and ultra-reliable connectivity is fundamental,” said Alain Bidaud, CTO of CRIANN. “Harnessing Adtran’s optical transport technology, we’ve boosted capacity across our fiber infrastructure while also rendering our services more resilient. The FSP 3000 enables a seamless transition from our existing transport network. What’s more, its modular architecture radically simplifies the upgrade process so we can augment the solution to efficiently and sustainably meet future demand.”
This major upgrade to CRIANN’s research and education network increases bandwidth across all three of its sites. Featuring Adtran’s FSP 3000 OpenFabric™ 1200, the new solution integrates an open and flexible OTN fabric with DWDM transponder functions that deliver up to 400Gbit/s per wavelength and supports multiple OTN and Ethernet client services from 10Gbit/s to 400Gbit/s on a single card. This enables CRIANN to boost transport capacity and ensures the network can easily scale to meet both current and future demands.
CRIANN has also deployed Adtran’s ALM in-service fiber monitoring platform, which provides rapid, detailed alerts in the event of any fiber disruption. Combined with Adtran’s Mosaic Network Controller and Fiber Director, it offers a sophisticated real-time geographic information system that delivers pinpoint accuracy in locating fiber issues. By empowering CRIANN’s maintenance team with a precise understanding of its fiber infrastructure, the technology helps reduce truck rolls, improves network availability and minimizes operating costs.
“Built on our FSP 3000 platform, CRIANN’s upgraded fiber infrastructure is ideally suited to meet the growing demands of research and education networks for higher capacity and greater reliability,” commented Stuart Broome, GM of EMEA sales at Adtran. “Harnessing our OpenFabric™ 1200 switchponder, the new solution supports Ethernet and OTN services up to 400Gbit/s. This technology simplifies operations and maximizes the potential of CRIANN’s fiber assets. With its new, robust network, CRIANN is empowering Normandy’s academic community to take their research to whole new levels.”
“At Axians, we believe in forging connections that matter, not just with technology but also through relationships. Our partnership with CRIANN and Adtran is a testament to this philosophy. Together, we’re ensuring CRIANN’s research and education network can adapt, evolve and meet future challenges,” noted Bruno Durand, GM of Axians communication and cloud Caen. “This deployment is about providing top-tier opportunities for scientists, teachers and students. By merging technical expertise with our commitment to delivering excellence, we’re ensuring that the region stays at the cutting edge of research and innovation.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104047734/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom